Collegium director files initial insider Form 3

COLLEGIUM PHARMACEUTICAL, INC. director Donovan Michael Glancy filed an initial Form 3, which is used to report insider share ownership when someone first becomes a reporting person.

Rhea-AI Filing Summary

COLLEGIUM PHARMACEUTICAL, INC. director Donovan Michael Glancy filed an initial Form 3, which is used to report insider share ownership when someone first becomes a reporting person. The excerpt shows no reported transactions or derivative positions, indicating this filing is purely an initial ownership disclosure.

Key Terms

Form 3, reporting person, director

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "Glancy Donovan Michael" } ]"

director financial

""is_director": 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the COLLEGIUM PHARMACEUTICAL (COLL) Form 3 filing show?

The Form 3 identifies Donovan Michael Glancy as a director of COLLEGIUM PHARMACEUTICAL, INC. It serves as his initial insider ownership disclosure and, in the provided excerpt, does not list specific transactions or derivative positions.

Does the COLLEGIUM PHARMACEUTICAL (COLL) Form 3 report any stock trades?

In the provided data, the Form 3 shows no reported transactions. Transaction counts for buying, selling, exercising options, gifts, tax withholding, and restructurings all appear as zero, indicating this filing functions as an initial ownership statement only.

Who is the reporting person in the COLLEGIUM PHARMACEUTICAL (COLL) Form 3?

The reporting person is Donovan Michael Glancy, listed with the role of director at COLLEGIUM PHARMACEUTICAL, INC. This means he is now subject to insider reporting obligations for his holdings in the company’s securities.

Are there derivative securities reported in this COLLEGIUM PHARMACEUTICAL Form 3?

The derivative summary in the provided Form 3 data is empty, and derivative transaction counts are zero. This indicates no options, warrants, or other derivative positions are detailed in the visible portion of the filing for Donovan Michael Glancy.

Why is a Form 3 filing important for COLLEGIUM PHARMACEUTICAL investors?

Form 3 establishes an insider’s baseline ownership when they become a reporting person. For COLLEGIUM PHARMACEUTICAL, it lets investors know that director Donovan Michael Glancy is now subject to ongoing disclosure of future changes in his holdings via Forms 4 and 5.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Glancy Donovan Michael

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/14/2026

3. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Colleen Tupper as Attorney-In-Fact For Michael Donovan	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)